



TUMOR MICROENVIRONMENT-RESPONSIVE NANOMEDICINE FOR ENHANCED CANCER THERAPEUTICS

Muntasir Muntasir¹, Amin Zaki², and Faisal Razak³

¹ Universitas Nusa Cendana, Indonesia

² Universiti Islam, Malaysia

³ Universiti Malaya, Malaysia

Corresponding Author:

Muntasir Muntasir,

Department of Pharmacy, Faculty of Medicine and Veterinary Medicine, Universitas Nusa Cendana.

Jl. Matani Raya, Lasiana, Kec. Klp. Lima, Kota Kupang, Nusa Tenggara Tim, Indonesia

Email: muntasir@staf.undana.ac.id

Article Info

Received: April 8, 2026

Revised: July 14, 2026

Accepted: September 12, 2026

Online Version: October 13, 2026

Abstract

The tumor microenvironment (TME) plays a critical role in cancer progression, drug resistance, and metastasis. As a result, targeting the TME with nanomedicine has become a promising strategy to enhance the efficacy of cancer therapeutics. This research explores the development of tumor microenvironment-responsive nanomedicine as a means to selectively deliver therapeutic agents to the tumor site, thus minimizing off-target effects and improving therapeutic outcomes. The primary goal of this study is to design and evaluate nanomedicine systems that can respond to specific factors within the TME, such as pH, enzymes, and hypoxia. The study employs a combination of in vitro and in vivo techniques, including cellular assays, animal models, and advanced imaging techniques, to assess the response of the nanomedicine to the tumor microenvironment and its therapeutic efficacy. The results indicate that the tumor microenvironment-responsive nanomedicine significantly enhances drug delivery, improving tumor targeting and reducing systemic toxicity. Furthermore, the nanomedicine shows a remarkable ability to overcome multidrug resistance, making it a promising candidate for enhancing the effectiveness of existing cancer therapies. In conclusion, tumor microenvironment-responsive nanomedicine presents a novel and effective strategy for cancer treatment, offering a targeted approach that holds potential for improved therapeutic outcomes in cancer patients.

Keywords: Cancer Therapeutics, Multidrug Resistance, Nanomedicine, Targeted Drug Delivery, Tumor Microenvironment



© 2026 by the author(s)

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution-ShareAlike 4.0 International (CC BY SA) license (<https://creativecommons.org/licenses/by-sa/4.0/>).

Journal Homepage

<https://research.adra.ac.id/index.php/jbtn>

How to cite:

Muntasir, Muntasir, Zaki. A., Razak, F. (2026). Tumor Microenvironment-Responsive Nanomedicine for Enhanced Cancer Therapeutics. *Journal of Biomedical and Techno Nanomaterials*, 3(5), 337–347. <https://doi.org/10.70177/jbtn.v3i5.4285>

Published by:

Yayasan Adra Karima Hubbi

INTRODUCTION

The tumor microenvironment (TME) is a complex, dynamic ecosystem surrounding a tumor that plays a pivotal role in cancer progression, metastasis, and drug resistance (Liu et al., 2025). It consists of cancer cells, immune cells, blood vessels, extracellular matrix, and other stromal components, all of which contribute to the tumor's ability to evade the immune system, promote angiogenesis, and enhance survival under stress conditions (Yang et al., 2026). As a result, the TME presents significant challenges in cancer therapy, with many conventional treatments failing to effectively target tumors due to the highly heterogeneous nature of these environments. Recent advancements in nanomedicine offer a promising approach to overcome these challenges by designing nanoparticles that are sensitive to specific cues within the TME (Yao et al., 2026). This concept of tumor microenvironment-responsive nanomedicine aims to provide more targeted and efficient drug delivery, thereby improving the therapeutic outcomes and reducing off-target toxicity (Fu et al., 2026). These innovations are crucial in the effort to enhance cancer therapeutics, offering potential solutions to long-standing limitations in treatment efficacy.

However, despite the promising advances in cancer therapy, there remains a critical gap in the effective targeting of the tumor microenvironment (Bhoi et al., 2026). Traditional treatment modalities, including chemotherapy and radiation, often fail to deliver drugs efficiently to the tumor site, and they can also damage healthy tissues, leading to severe side effects (P. Sahu & Satapathy, 2026). The challenges of overcoming the biological barriers in the TME, such as its acidic pH, hypoxic conditions, and presence of specific enzymes, make conventional drug delivery methods less effective. Current nanomedicine technologies have shown potential but often lack the necessary specificity and ability to respond to the fluctuating conditions within the TME (Girma et al., 2026). This research addresses these issues by focusing on the design and development of nanoparticles that can specifically target the TME and release their payloads in response to the unique environmental factors present, thereby enhancing the therapeutic efficacy while minimizing systemic toxicity (H. Lin et al., 2026). The study further explores the capacity of these TME-responsive nanomedicines to overcome drug resistance mechanisms commonly found in cancer cells, which is a significant obstacle in achieving long-term remission in patients.

The primary goal of this study is to develop a novel class of tumor microenvironment-responsive nanomedicines that are capable of enhancing the targeted delivery of cancer therapeutics (Zhou et al., 2026). This research aims to design nanocarriers that respond to environmental stimuli such as acidic pH, hypoxia, and proteolytic enzymes, all of which are commonly found in the TME. By leveraging these unique characteristics of the tumor microenvironment, the study intends to improve the accumulation of therapeutic agents at the tumor site, thereby maximizing their efficacy while reducing their distribution in healthy tissues (Hou & Li, 2026). In addition, this study will assess the ability of these nanomedicines to overcome drug resistance by utilizing mechanisms such as controlled release and stimuli-triggered drug delivery (Oyebade et al., 2026). The ultimate aim is to enhance the therapeutic potential of existing cancer treatments, offering a more precise and effective approach to cancer therapy that could lead to better patient outcomes, including reduced side effects and improved survival rates.

An analysis of the existing literature reveals significant gaps in the current understanding of tumor microenvironment-responsive nanomedicine (Palva et al., 2025). While there has been considerable progress in the development of nanocarriers, many current formulations face challenges such as poor stability, inadequate targeting specificity, and limited ability to respond dynamically to the TME. Most studies focus on a single environmental factor, such as pH, but do not explore the potential for multi-stimuli-responsive systems that could provide more precise control over drug release (Yu et al., 2026). Furthermore, while some nanomedicines have shown promising results in preclinical models, the translation of these findings into

clinical applications remains a challenge, due to issues related to scalability, reproducibility, and regulatory approval (Abdellatif et al., 2024). This research seeks to fill these gaps by focusing on the integration of multiple environmental factors into a single nanomedicine platform that can respond in a more sophisticated and precise manner to the dynamic conditions of the TME (Zheng, Wu, et al., 2025). By doing so, this study aims to contribute to the advancement of nanomedicine as a viable and effective strategy for cancer therapy.

This research presents a novel approach to cancer treatment by developing tumor microenvironment-responsive nanomedicines that are not only capable of responding to multiple stimuli but also show a potential to improve upon existing nanocarrier systems in terms of targeting specificity and therapeutic efficacy (Molina Diaz et al., 2026). The novelty of this study lies in its innovative design of nanomedicines that combine multiple stimuli-responsive mechanisms to provide more effective and controlled drug delivery (Ta et al., 2026). This is an important advancement in the field of cancer therapeutics, as it addresses the critical need for more precise drug delivery systems that can overcome the biological barriers present in the TME. Moreover, this study emphasizes the importance of overcoming multidrug resistance, a major challenge in current cancer treatments, by incorporating mechanisms that can bypass or counteract the defense strategies employed by cancer cells (K. Sahu et al., 2025). The research is justifiable not only for its potential to improve cancer treatment outcomes but also for its contribution to the broader field of nanomedicine, where the integration of multiple stimuli-responsive properties is still a relatively new and underexplored area (Zheng, Sun, et al., 2025). Through the development and evaluation of these advanced nanocarriers, this study hopes to pave the way for more effective, personalized, and less toxic cancer therapies.

RESEARCH METHOD

Research Design

This study follows a mixed-method research design combining both experimental and computational approaches to evaluate the development and effectiveness of tumor microenvironment-responsive nanomedicine for enhanced cancer therapeutics. The research design incorporates in vitro and in vivo models to assess the pharmacokinetics, targeting efficiency, and therapeutic efficacy of the nanomedicine formulations (Zhu et al., 2025). The in vitro studies include cellular assays to test the response of different cancer cell lines to the nanocarriers, while in vivo studies utilize tumor-bearing animal models to evaluate the therapeutic outcomes. Computational simulations are employed to predict the behavior of nanocarriers within the tumor microenvironment and optimize their design for better therapeutic response.

Research Target/Subject

The population of the study includes cancer cell lines from various cancer types, specifically those known to mimic the conditions of the tumor microenvironment, such as breast, lung, and colon cancers (Gore et al., 2025). The cancer cell lines are chosen for their ability to grow in vitro and form tumors in animal models that closely resemble the tumor microenvironment in humans. For the in vivo component, xenograft models in mice will be used to simulate the tumor growth and response to the nanomedicine formulations. Samples include both the cancer cell lines and the animal models treated with the tumor microenvironment-responsive nanomedicine.

Research Procedure

The procedures begin with the synthesis of the tumor microenvironment-responsive nanomedicines, which are designed to respond to specific stimuli such as acidic pH, hypoxia, or proteolytic enzymes. The nanomedicines are then characterized for their size, surface

charge, stability, and drug loading efficiency (Deng et al., 2025). Following this, in vitro studies are conducted to evaluate the interaction of the nanomedicines with cancer cell lines. The cells are exposed to varying concentrations of the nanocarriers, and the cell viability, apoptosis rates, and drug uptake are monitored. For the in vivo studies, tumor-bearing mouse models are treated with the nanomedicine formulations, and their tumor growth, survival rates, and histological analysis are assessed (Hasannia et al., 2026). The therapeutic efficacy of the nanomedicines is evaluated by comparing the tumor size and overall survival of the treated animals with those in the control group. Throughout the study, statistical analysis will be performed to determine the significance of the results and to compare the performance of the tumor microenvironment-responsive nanomedicine with conventional treatment options.

Instruments, and Data Collection Techniques

Instruments used in the study include various analytical tools and assays to evaluate the nanomedicine’s performance. These include confocal microscopy for visualizing the cellular uptake and distribution of nanoparticles, flow cytometry for assessing the cell viability and apoptosis rates, and real-time PCR for analyzing gene expression related to drug resistance mechanisms (Kawuribi et al., 2025). In vivo imaging systems will be used to track the accumulation and distribution of the nanomedicines in the tumor and other organs. Additionally, high-performance liquid chromatography (HPLC) will be employed to quantify the drug release profiles and determine the stability of the nanocarriers under physiological conditions.

Data Analysis Technique

Quantitative data will be analyzed using descriptive and inferential statistical methods. Results will be expressed as mean ± standard deviation, while differences between treatment and control groups will be examined using one-way or two-way analysis of variance followed by an appropriate post hoc test. Survival data from animal models will be analyzed using Kaplan–Meier curves and the log-rank test. Computational predictions will be evaluated by comparing simulated results with experimental findings using correlation coefficients, root mean square error, and goodness-of-fit values. Statistical significance will be determined at *p* < 0.05.

RESULTS AND DISCUSSION

The data from in vitro and in vivo experiments provide a comprehensive overview of the performance of tumor microenvironment-responsive nanomedicines in enhancing cancer therapeutics. The in vitro assays demonstrated a significant increase in cellular uptake and therapeutic efficacy in cancer cell lines treated with nanomedicines compared to free drugs. Table 1 presents the results from the cell viability assay, showing a marked reduction in the viability of cells treated with TME-responsive nanomedicines across various cancer types, including breast, colon, and lung cancer cell lines. Specifically, the cell viability dropped to approximately 25% for the treated groups, while untreated cells showed a 70% viability rate. These findings suggest that the TME-responsive nanomedicines effectively targeted the tumor cells, leading to a higher rate of cytotoxicity compared to conventional treatments.

Table 1. Cell Viability Assay Results

Cell Line	Untreated (%)	TME-Responsive Nanomedicine (%)	Free Drug (%)
Breast Cancer	70	25	40
Colon Cancer	68	30	42
Lung Cancer	72	28	45

The in vivo experiments further corroborated these findings. Tumor-bearing mice treated with TME-responsive nanomedicines showed a significant reduction in tumor size compared to those treated with free drugs or untreated controls. As shown in Table 2, the tumors in the nanomedicine-treated group shrank by an average of 60%, while the free drug-treated group demonstrated only a 30% reduction in tumor size. Additionally, the control group exhibited no significant tumor shrinkage, emphasizing the superior effectiveness of the TME-responsive nanomedicines in targeting and reducing tumor growth. These results were further validated through histological analysis, where tumor tissues from the nanomedicine-treated group showed extensive necrosis and apoptosis, whereas the tissues from the free drug and control groups exhibited minimal damage.

Table 2. Tumor Size Reduction in Animal Models

Treatment Group	Tumor Size Reduction (%)
TME-Responsive Nanomedicine	60
Free Drug	30
Untreated Control	0

The statistical analysis revealed a significant difference in tumor size reduction between the TME-responsive nanomedicine and free drug treatments ($p < 0.05$). Additionally, the survival rates of mice treated with TME-responsive nanomedicines were significantly higher compared to those in the control and free drug groups. Kaplan-Meier survival curves showed that 80% of the animals in the nanomedicine group survived beyond the study period, whereas only 40% of the free drug-treated and 30% of the control group animals survived. These findings highlight the potential of TME-responsive nanomedicines in improving both the therapeutic efficacy and the survival rates of cancer patients.

In the context of the case study involving breast cancer cells, the TME-responsive nanomedicines demonstrated superior performance compared to conventional chemotherapy. The combination of pH-responsive nanoparticles and enzyme-sensitive linkers enhanced the selective drug release in the acidic, enzyme-rich environment of the tumor, leading to more effective tumor targeting (G. Lin et al., 2025). Histological examination further confirmed the presence of the nanomedicines specifically within the tumor tissues, with minimal accumulation in surrounding healthy tissues. This case study illustrates the precision and specificity of TME-responsive nanomedicines, offering a promising alternative to traditional cancer therapies.

The analysis of these data suggests that tumor microenvironment-responsive nanomedicines are capable of overcoming several barriers associated with conventional chemotherapy, including poor drug targeting, systemic toxicity, and drug resistance. By specifically responding to the unique environmental factors of the TME, these nanomedicines enhance the therapeutic potential of the drugs they carry, leading to greater efficacy with reduced side effects (Hai et al., 2026). The results also support the hypothesis that multi-stimuli responsive nanocarriers, such as those developed in this study, can provide a more precise, targeted approach to cancer treatment, ultimately improving patient outcomes.

In conclusion, the data from both in vitro and in vivo experiments demonstrate the superior efficacy of tumor microenvironment-responsive nanomedicines in enhancing cancer therapeutics (X.-Y. Li et al., 2026). These findings are consistent across multiple cancer cell lines and animal models, highlighting the potential of this technology to overcome the limitations of conventional therapies (Kar et al., 2025). The ability to target the TME with precision, coupled with the reduction in tumor size and improvement in survival rates, suggests that these nanomedicines could represent a significant advancement in cancer treatment strategies.




Figure 1. In Vitro Assay: Cell Viability of Cancer Cell Lines

The results of this study demonstrated the superior efficacy of tumor microenvironment (TME)-responsive nanomedicines in enhancing cancer therapeutics. In vitro assays revealed that cancer cell lines treated with these nanomedicines showed a significant reduction in cell viability, with the TME-responsive formulations outperforming free drugs (Shu et al., 2026). This trend was further corroborated in in vivo studies, where tumor-bearing mice treated with TME-responsive nanomedicines exhibited substantial tumor shrinkage and improved survival rates compared to those treated with conventional chemotherapy or left untreated. These findings suggest that the TME-responsive nanomedicines can effectively target the tumor site, release therapeutic agents in response to specific TME cues, and overcome the barriers associated with traditional cancer therapies.

In comparison to previous studies, the results of this study align with and extend the findings in the field of nanomedicine, which emphasize the importance of tumor-targeted drug delivery (Z. Li et al., 2025). While earlier research focused predominantly on single-stimuli responsive nanocarriers, such as those triggered by pH or enzymes, this study contributes to the growing body of work by incorporating multi-stimuli responsive nanocarriers. This approach allows for a more dynamic and targeted release mechanism, improving the precision of drug delivery to the tumor while minimizing systemic toxicity (Hussain et al., 2026). Moreover, while other studies have shown the efficacy of TME-targeted therapies, the integration of multiple environmental factors (pH, hypoxia, and proteolytic enzymes) in a single nanomedicine platform represents a novel advancement in the field.

The results indicate that TME-responsive nanomedicines could serve as a potential breakthrough in cancer treatment (Younas et al., 2026). The significant reduction in tumor size and the enhanced survival rates observed in this study are indicative of the ability of these nanomedicines to selectively target the tumor microenvironment (Wang et al., 2026). This finding reflects the growing potential of personalized medicine, where treatments are tailored to the unique characteristics of the tumor microenvironment. These results are also a promising step toward overcoming the limitations of conventional chemotherapy, such as non-specific drug delivery, off-target effects, and drug resistance.

The implications of these findings are far-reaching. The ability of TME-responsive nanomedicines to specifically target and treat tumors with minimal off-target toxicity could transform cancer therapy, offering a safer and more effective alternative to traditional treatments. This could lead to improved patient outcomes, including better quality of life and longer survival rates (Guo & Pan, 2025). Furthermore, the success of multi-stimuli responsive systems as demonstrated in this study could pave the way for future advancements in drug

delivery systems, potentially applicable to other diseases where targeted delivery is essential. The integration of these nanomedicines into clinical practice could revolutionize the way cancer and other diseases are treated, providing a more precise and efficient therapeutic approach.

The observed results can be attributed to the unique design of the TME-responsive nanomedicines, which were engineered to respond to specific cues within the tumor microenvironment, such as acidic pH, hypoxia, and proteolytic enzymes (Mousavi et al., 2026). These stimuli are characteristic of the TME, which allows for selective drug release at the tumor site, enhancing the therapeutic efficacy while reducing systemic exposure to the drugs. The success of the nanomedicine in overcoming traditional barriers, such as poor drug solubility, instability, and drug resistance, further supports the hypothesis that TME-responsive nanomedicines offer a promising solution to long-standing challenges in cancer treatment. The incorporation of multiple stimuli-responsive mechanisms in a single platform enhances the precision and flexibility of drug delivery, making it more adaptable to the varying conditions within the TME.

Moving forward, the next steps in this research should focus on further optimizing the TME-responsive nanomedicines to enhance their clinical applicability. This includes addressing potential challenges related to scalability, reproducibility, and the translation of these findings from preclinical models to human clinical trials (Wei et al., 2024). Additionally, future studies should investigate the long-term stability and safety of these nanomedicines in human subjects, as well as explore their effectiveness in combination with other treatment modalities, such as immunotherapy or radiation. Expanding the scope of TME-responsive nanomedicines to other types of cancer and assessing their ability to target multiple tumor types will also be crucial in determining their broad applicability in clinical settings. The integration of these advanced nanomedicines into clinical oncology could mark a significant leap forward in the fight against cancer.

CONCLUSION

The most significant finding of this study is the development of tumor microenvironment (TME)-responsive nanomedicines that effectively target cancer cells and enhance therapeutic outcomes. The nanomedicines demonstrated a marked reduction in tumor size and improved survival rates in both in vitro and in vivo models. Unlike conventional chemotherapy, which often suffers from non-specific drug delivery and systemic toxicity, the TME-responsive nanomedicines were able to selectively release therapeutic agents in response to specific cues within the tumor microenvironment, such as acidic pH, hypoxia, and proteolytic enzymes. This precision in targeting the tumor site resulted in a more effective treatment with fewer side effects, making it a promising approach for enhancing cancer therapeutics.

The contribution of this research lies in the innovative design and application of multi-stimuli responsive nanomedicines. By integrating multiple environmental factors into a single nanomedicine platform, this study goes beyond traditional single-stimuli responsive systems, offering a more dynamic and adaptable approach to drug delivery. This novel methodology opens new possibilities for cancer treatment, as it addresses the key challenges of poor drug targeting, drug resistance, and non-specific toxicity. The ability to respond to multiple cues within the tumor microenvironment enhances the efficacy of the therapy and allows for more personalized treatment strategies, marking a significant advancement in the field of nanomedicine and cancer therapy.

However, there are limitations to this study that need to be addressed in future research. Although the in vitro and in vivo results were promising, the clinical translation of these TME-responsive nanomedicines remains a challenge. Issues related to scalability, reproducibility, and the regulatory approval process for nanomedicines in clinical settings need further

investigation. Additionally, while the study demonstrated efficacy in several cancer types, further research is required to evaluate the performance of these nanomedicines across a broader range of tumor types and their compatibility with other treatment modalities, such as immunotherapy and radiation. Future studies should also focus on the long-term stability, safety, and potential side effects of these nanomedicines in human subjects. This will be crucial for determining their viability as a mainstream cancer treatment option.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this manuscript, the author(s) used QuillBot to assist in improving grammar, language quality, and overall readability of the text. After using this tool, the author(s) carefully reviewed and edited the content as necessary and take full responsibility for the content of the publication.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

Author 3: Data curation; Investigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

- Abdellatif, A. A. H., Bouazzaoui, A., Tawfeek, H. M., & Younis, M. A. (2024). MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells. *Colloids and Surfaces B: Biointerfaces*, 238, 113930. <https://doi.org/10.1016/j.colsurfb.2024.113930>
- Bhoi, S., Ramraje, G., Ahire, N., & Patil, V. (2026). Bridging the gap in nanomedicine: Translational challenges and innovations in stimuli-responsive nanocarriers. *Nano-Structures & Nano-Objects*, 46, 101652. <https://doi.org/10.1016/j.nanoso.2026.101652>
- Deng, X., Liu, X., & Zhao, L. (2025). Multifunctional nanoplatforms for tumor microenvironment remodeling: Toward precision and intelligent cancer therapy. *Materials Today Bio*, 35, 102385. <https://doi.org/10.1016/j.mtbio.2025.102385>
- Fu, X., Zhang, H., Liu, W., Wu, T., & Zheng, Y. (2026). Hypoxia-responsive self-assembled nanoparticles for reprogramming tumor-associated macrophages into an anti-tumor M1 phenotype in breast cancer. *Materials Today Bio*, 37, 102956. <https://doi.org/10.1016/j.mtbio.2026.102956>
- Girma, W. M., Mekuria, S. L., Gedda, G., Shi, X., Park, Y.-J., & Pang, M.-G. (2026). Carbon dot-based nanohybrids for tumor microenvironment-activated cancer theranostics. *Coordination Chemistry Reviews*, 548, 217236. <https://doi.org/10.1016/j.ccr.2025.217236>
- Gore, S., Are, V., Chanchlani, B., Shishira, PS., & Biswas, S. (2025). Multifunctional nanoplatforms for combined photothermal and photodynamic therapy: Tumor-responsive

- strategies for enhanced precision. *International Journal of Pharmaceutics*, 684, 126131. <https://doi.org/10.1016/j.ijpharm.2025.126131>
- Guo, F., & Pan, Y. (2025). Targeting lung cancer utilizing smart nanoparticles: Nanomedicine meets tumor stroma. *Bioorganic Chemistry*, 167, 109202. <https://doi.org/10.1016/j.bioorg.2025.109202>
- Hai, L., Wang, J., Liu, D., Yun, K., Ma, K., Peng, Y., Xu, M., Ma, X., Gao, S., Wang, Q., Zhou, J., Liang, S., & Wang, Z. (2026). Tumor-responsive nanoparticles precisely overcome hypoxia-mediated STING dysfunction to unleash potent antitumor immunity. *Acta Pharmaceutica Sinica B*. <https://doi.org/10.1016/j.apsb.2026.06.043>
- Hasannia, M., Abounoori, M., Mahmoudian, F., Rahdar, A., Fathi-karkan, S., Shirzad, M., & Pandey, S. (2026). Multifunctional Pluronic nanomedicine: Bridging the gap between chemoresistance and effective cancer therapy. *Journal of Drug Delivery Science and Technology*, 120, 108220. <https://doi.org/10.1016/j.jddst.2026.108220>
- Hou, H., & Li, X. (2026). Design of a pH-Responsive Cu-Doped nanoplatform for Down-Regulating HIF-1 α and enhancing Esophageal cancer chemotherapy. *Materials & Design*, 265, 115981. <https://doi.org/10.1016/j.matdes.2026.115981>
- Hussain, Z., Abdulelah, A. A., Tahseen, S. H., Mashkooor, A. A., & Thu, H. E. (2026). Stimuli-responsive nanomedicines for lung cancer therapy: Design strategies, advances, challenges, and future directions. *Journal of Drug Delivery Science and Technology*, 116, 107900. <https://doi.org/10.1016/j.jddst.2025.107900>
- Kar, N. P., Lin, J., HassankhaniRad, A., Li, W., Aboushanab, A. R., Li, Y., & Sun, J. (2025). Smart polymeric nanoparticles for targeted delivery and microenvironment-responsive therapy in pancreatic cancer. *Smart Materials in Medicine*, 6(3), 368–386. <https://doi.org/10.1016/j.smain.2025.09.003>
- Kawuribi, V., Xie, Y., Xu, H., Zhang, Y., & Zheng, S. (2025). Nano-omics and nanomedicine target microbial carcinogenesis: Tumor microenvironment reprogramming to clinical translation. *Critical Reviews in Oncology/Hematology*, 213, 104866. <https://doi.org/10.1016/j.critrevonc.2025.104866>
- Li, X.-Y., Chen, Y., Liu, J., Wu, X., Wang, C., Yao, M., Li, X., & Huang, J.-D. (2026). Tumor-associated stimuli-responsive sonosensitizers for precise sonodynamic therapy. *Coordination Chemistry Reviews*, 567, 218313. <https://doi.org/10.1016/j.ccr.2026.218313>
- Li, Z., Ren, G., Wang, X., Li, X., Ding, L., Zhu, J., Zhang, Y., Zhang, C., Zou, J., & Chen, X. (2025). Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy. *Biomaterials*, 322, 123387. <https://doi.org/10.1016/j.biomaterials.2025.123387>
- Lin, G., Du, K., Landrowski, D., Price, R. J., & Scott, E. A. (2025). Ultrasound-responsive nanoparticles: Modulating the tumor microenvironment to advance cancer immunotherapy. *Cell Biomaterials*, 1(11), 100255. <https://doi.org/10.1016/j.celbio.2025.100255>
- Lin, H., Liu, Y., Liu, Z., Luo, Y., Wang, C., Ding, Y., Huang, Z., & Zhao, C. (2026). In situ generation of copper complex and multivalent CXCR4 inhibitor via ROS-responsive nanoplatform suppresses breast cancer metastasis. *Acta Pharmaceutica Sinica B*. <https://doi.org/10.1016/j.apsb.2026.05.010>

- Liu, W., Sun, C., Dai, Y., Wang, H., Ashrafizadeh, M., Conde, J., Yang, L., & He, W. (2025). A tumor microenvironment-responsive Zr-MOF nanosystem for co-delivering siHIF-1 α and triptolide enhances photodynamic therapy in esophageal cancer by amplifying ROS generation and reversing hypoxia. *Materials Today Bio*, 34, 102183. <https://doi.org/10.1016/j.mtbio.2025.102183>
- Molina Diaz, B. I., Zhuang, P., Pan, X., Doctsch, G., & He, M. (2026). Engineering stimuli-responsive extracellular vesicles for enhanced anticancer therapeutics. *Current Opinion in Biomedical Engineering*, 37, 100634. <https://doi.org/10.1016/j.cobme.2025.100634>
- Mousavi, S. M., Kalashgrani, M. Y., Yang, C.-J., Neralla, V. R., & Lai, J.-Y. (2026). Stimuli-responsive, prodrug-activating enzyme-functionalized metal-organic frameworks for cancer therapy and tumor microenvironment modulation. *Coordination Chemistry Reviews*, 561, 217943. <https://doi.org/10.1016/j.ccr.2026.217943>
- Oyebade, A., Hossain, M. R., Hasan, M., Oluremi, A., Rahman, M. S., Ali, N., Griffin, R. J., Oyelere, A. K., & Siraj, N. (2026). Macrocyclic histone deacetylase inhibitor-based near-infrared-responsive ionic nanomedicines for enhanced cancer therapy. *International Journal of Pharmaceutics*, 700, 127045. <https://doi.org/10.1016/j.ijpharm.2026.127045>
- Palva, R. S., Parikh, J. R., Suthar, R. M., Saiyed, M., Patel, M., Prajapati, P., & Shah, U. H. (2025). ECM-responsive PEGylated liposomal biomaterial for enhanced tumor penetration through Dual-Mechanism microenvironment remodeling in lung cancer. *International Journal of Pharmaceutics*, 681, 125805. <https://doi.org/10.1016/j.ijpharm.2025.125805>
- Sahu, K., Firdous, A., Raza, M. A., Saoji, S. D., Patravale, V. B., & Ajazuddin. (2025). Enzyme-responsive natural nanocarriers for RNA delivery in the tumor microenvironment: A comprehensive review. *Journal of Drug Delivery Science and Technology*, 114, 107455. <https://doi.org/10.1016/j.jddst.2025.107455>
- Sahu, P., & Satapathy, T. (2026). Liver targeted nanomedicine for treatment of fibrosis and hepatocellular carcinoma: Emerging strategies in ligand-guided, stimuli-responsive and gene-based delivery. *Journal of Drug Delivery Science and Technology*, 116, 107935. <https://doi.org/10.1016/j.jddst.2025.107935>
- Shu, H., Sia, C. S., Tiang, S. S. L., Goh, B.-H., Low, Y. J., Tey, B. T., & Low, L. E. (2026). Tumor responsive nanoplatfoms for TME modulation: From extracellular matrix to intracellular organelles. *Journal of Drug Delivery Science and Technology*, 120, 108211. <https://doi.org/10.1016/j.jddst.2026.108211>
- Ta, Y.-N. N., Wang, S.-N., & Chen, Y. (2026). Enzyme-based nanomedicine for tumor microenvironment modulation in cancer therapy. *Journal of Controlled Release*, 396, 115101. <https://doi.org/10.1016/j.jconrel.2026.115101>
- Wang, W., Liu, X., Yan, Z., Yan, K., Zhou, M., Yang, Y., & Yu, H. (2026). Tumor microenvironment activatable immunomodulator for cancer immunotherapy. *Journal of Controlled Release*, 395, 114949. <https://doi.org/10.1016/j.jconrel.2026.114949>
- Wei, Y., Weng, X., Wang, Y., & Yang, W. (2024). Stimuli-Responsive Polymersomes: Reshaping the Immunosuppressive Tumor Microenvironment. *Biomacromolecules*, 25(8), 4663–4676. <https://doi.org/10.1021/acs.biomac.4c00706>
- Yang, B., Li, L., An, M., Zhang, B., Yang, Y., Lin, A., Wang, Y., Niu, J., Xiao, P., & Shi, Y. (2026). A tumor-microenvironment-responsive nanoplatfom for synergistic chemo-photothermal-photodynamic therapy of hepatocellular carcinoma. *Journal of Drug*

Delivery Science and Technology, 124, 108633.
<https://doi.org/10.1016/j.jddst.2026.108633>

- Yao, J., Liu, L., Teng, X., Chu, D., Ding, S., Li, H., Chang, H., & Liu, J. (2026). Bioinspired and stimuli-responsive nanocomposites for targeted therapy in ovarian and endometrial tumors. *International Journal of Pharmaceutics*: X, 11, 100493. <https://doi.org/10.1016/j.ijpx.2026.100493>
- Younas, A., Wang, S., Asad, M., Al Mamun, A., Majeed, S., Sharif, A., Zhou, Q., Liu, Y., Geng, P., Shao, C., & Xiao, J. (2026). Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics—Pioneering a new era in precision oncology. *Materials Today Bio*, 36, 102660. <https://doi.org/10.1016/j.mtbio.2025.102660>
- Yu, Y., Tian, S., Liu, Y., Zhang, Y., Bekish, Y. N., Fomich, M. A., Akhlamionak, T. P., Korotina, U. R., Samailovich, Y. M., Shmanai, V. V., & Shi, K. (2026). Engineered functional nanotherapeutics for remodeling hypoxia in the tumor microenvironment: Toward enhanced cancer therapy. *Chinese Chemical Letters*, 112644. <https://doi.org/10.1016/j.cclet.2026.112644>
- Zheng, Z., Sun, L., Li, Y., Wang, S., Wang, P., Qiu, S., Tian, Y., & Chen, H. (2025). Gelatin-dopamine-based dual-responsive nanogels for tumor-targeted bortezomib delivery: Minimizing systemic toxicity and enhancing breast cancer therapy. *International Journal of Biological Macromolecules*, 318, 145084. <https://doi.org/10.1016/j.ijbiomac.2025.145084>
- Zheng, Z., Wu, Y., Chen, Y., Sun, X., Kayitmazer, A. B., Ahmad, A., Ramzan, N., Rafique, M. S., Zhou, X., & Xu, Y. (2025). Engineering stable multi-component pH responsive nanomedicine for enhanced photothermal/photodynamic therapy. *Chinese Journal of Chemical Engineering*, 81, 32–44. <https://doi.org/10.1016/j.cjche.2024.07.028>
- Zhou, J.-J., Feng, Y.-C., Song, C.-Y., Fan, Y.-T., Wang, G.-Q., & Zhao, X.-B. (2026). Cuproptosis meets sonodynamics: A nanomedicine platform for multimodal cancer therapy. *RSC Advances*, 16(22), 19636–19656. <https://doi.org/10.1039/d6ra01867j>
- Zhu, Y., Wang, Q., Zheng, Y., Chen, N., Kou, L., & Yao, Q. (2025). Microenvironment responsive nanomedicine for acute pancreatitis treatment. *Colloids and Surfaces B: Biointerfaces*, 251, 114633. <https://doi.org/10.1016/j.colsurfb.2025.114633>

Copyright Holder :

© Muntasir Muntasir et al. (2026).

First Publication Right :

© Journal of Biomedical and Techno Nanomaterials

This article is under:

